Document:

EX-10.8

 Exhibit 10.8 

Third Harmonic Bio, Inc. 
 July 2, 2021 

Natalie Holles 
 Dear Natalie: 

On behalf of Third Harmonic Bio, Inc. (the “Company”), I am pleased to offer you employment with the Company on the following terms and
conditions. 
 1. Position. You will be employed by the Company on a full-time basis as its Chief Executive Officer, reporting to the Company’s
Board of Directors (the “Board”). It is contemplated that you will commence employment on August 9, 2021 (the “Start Date”). Although the Company agrees that your work for the Company will not principally be
provided at the Company’s office in Cambridge, Massachusetts, you shall work out of the Company’s office in Cambridge, Massachusetts with reasonable frequency, subject to the requirements of the Company’s business and operations as
may be agreed by you and the Company. You agree to devote your full business time, best efforts, skill, knowledge, attention and energies to the advancement of the Company’s business and interests and to the performance of your duties and
responsibilities as an employee of the Company, and, except for those activities set forth on Exhibit A to this offer letter, you shall not engage in any other employment, consulting or other business activity with any third party without the
prior written consent of the Company. In addition, you will be elected to serve as a director on the Board commencing on the Start Date. 
 2. Base
Salary. You will receive a base salary at the semi-monthly rate of $20,833, which is equivalent to $500,000 on an annualized basis (the “Base Salary”). All payments of Base Salary will be made in accordance with the
Company’s standard payroll schedule and subject to applicable deductions and withholdings. The Base Salary will be subject to adjustment, as determined by the Board in its discretion. 

3. Annual Bonus. Following the end of each fiscal year, you will be eligible to receive an annual incentive bonus of up to fifty percent (50%) of your
annualized Base Salary (the “Target Bonus”). The actual bonus awarded for a fiscal year will be based on your performance and the Company’s performance that year against criteria to be established by the Board, such bonus and
such criteria as determined by the Board in its sole discretion. You must remain employed by the Company as of the last day of a fiscal year in order to be eligible for and to earn a bonus for such year. Any bonus for the 2021 fiscal year will be pro- rated based on your Start Date. 
 4. Equity. Subject to the approval of the Board, the Company shall grant to
you two stock option awards to purchase up to an aggregate of 2,753,352 shares of the Company’s common stock (the “Option Grants”) as follows: 

a. A stock option award to purchase up to 2,431,087 shares of the Company’s common stock, which shall vest as to twenty-five percent (25%)
of the underlying shares on the first anniversary of the Start Date, and as to the balance in equal quarterly installments of 6.25% thereafter until the fourth anniversary of the Start Date; and 

  
 1 

 b. A stock option award to purchase up to 322,265 shares of the Company’s common stock,
which shall not be subject to vesting until either the occurrence of the Second Tranche Closing (as defined in the Series A-3 Preferred Stock Purchase Agreement dated as of February 24, 2021 (the
“Purchase Agreement”)) or the optional early purchase of a majority of the Second Tranche Shares (as defined in the Purchase Agreement) under the Purchase Agreement (the earlier of these events, the “Second Tranche
Funding”) and which from the Second Tranche Funding shall vest (or be deemed to have vested) as to twenty-five percent (25%) of the underlying shares on the first anniversary of the Start Date, and as to the balance in equal quarterly
installments of 6.25% thereafter until the fourth anniversary of the Start Date; provided, however, that (i) there can be no assurance that the Second Tranche Closing shall occur, and (ii) if the Second Tranche Funding does not occur and
may no longer occur under the Purchase Agreement for any or no reason (such event, a “Second Tranche Expiration”), you shall not be entitled to exercise any shares subject to the award contemplated by this paragraph b. which have
not already been exercised early for shares of restricted stock. Moreover, in the event of a Second Tranche Expiration, the Company shall be entitled to repurchase any shares subject to the award contemplated by this paragraph b. that have been
exercised early for shares of restricted stock in accordance with the Grant Documents (as defined below). 
 c. The Option Grants will be
subject to the terms and conditions of the stock option agreements and the Company’s 2019 Stock Incentive Plan in all respects (the “Grant Documents”), and shall have an exercise price per share equal to the fair market value
of the Company’s common stock on the date of grant, as determined by the Board in its discretion. The stock option agreements for the Option Grants shall allow for early exercise of unvested options for shares of restricted stock subject to
vesting in accordance with the vesting schedule for the applicable Option Grant. In addition, provided that you remain employed by the Company through the applicable grant date, the Company will grant to you additional stock option grants and/or
awards of restricted shares of common stock (i) in connection with the Second Tranche Funding, in an amount sufficient to bring your total equity ownership of the Company to 5.5% of the Company’s fully diluted capitalization as of
immediately following the Second Tranche Funding (including for the purpose of calculating the fully diluted capitalization of the Company, the 5,859,376 Second Tranche Shares contemplated to be issued and sold pursuant to the Purchase Agreement and
any increase in the number of shares issued or issuable under the Company’s 2019 Stock Incentive Plan after the date hereof, but excluding any other shares of capital stock or other securities convertible, exercisable or exchangeable for
capital stock issued or agreed to be issued after the date hereof, including any additional shares of Series A-3 Preferred Stock) and (ii) in connection with any Series B Preferred Stock financing or
other subsequent equity financing that the Company may conduct prior to the Company’s IPO, as determined by the Board in its sole discretion after giving consideration to Company performance, the terms of the financing and equity positions of
similarly titled executives at comparable companies (collectively, “Additional Grants”). 
 If you choose to exercise the Options Grants
(or any portion thereof), to facilitate such exercise, the Company shall make a loan to you for 100% of the purchase price of the shares subject to the Option Grants, which loan shall be made pursuant to the Form of Secured Partial Recourse
Promissory Note attached hereto as Exhibit B. 
 5. Benefits. You may participate in the benefit programs offered by the Company to its
employees from time to time, provided that you are eligible under (and subject to all provisions of) the plan documents that govern those programs. Benefits are subject to change at any time in the Company’s sole discretion. You will also be
entitled to paid vacation each year in accordance with the terms and conditions set forth in the Company’s vacation policy as in effect from time to time, but for avoidance of doubt, you will accrue no less than three weeks paid vacation per
year. You shall also be entitled to receive reimbursement for all 

  
 2 

 
reasonable business expenses incurred by you in performing your services to the Company (which shall include reasonable lodging costs and business-class airfare costs you incur as a result of you
providing services to the Company in its Cambridge, Massachusetts office location) in accordance with the policies and procedures then in effect and established by the Company. 

6. Severance Benefits. 
 a.
General. Either party may terminate your employment relationship hereunder at any time for any reason by providing written notice to the other party; provided that if that Company terminates your employment for Cause (as defined below), the
Company shall comply with Section 12(b) hereof. If you are subject to an Involuntary Termination (as defined below), then you will be entitled to the benefits described in this Section 6. However, this Section 6 will not apply unless
you: (i) have returned all Company property in your possession on or prior to your last day of employment and (ii) have entered into a separation agreement that has become enforceable and irrevocable and that includes a general release of
all employment-related claims that you may have against the Company or persons affiliated with the Company (the “Separation Agreement”). Notwithstanding the foregoing, no term of this offer letter or the Separation Agreement shall
impact or affect, in any way, your rights with respect to, and the Separation Agreement shall not include a waiver or release of any claims related to: (w) your status as a stockholder or equity holder of the Company or any rights you have
under the terms of any Grant Document or any other equity award or agreement between you and the Company, including any claims with respect to the Option Grants, any Additional Grant or other equity owned or held by you at the time your employment
is terminated, (x) any rights to indemnification from the Company, pursuant to any applicable governing documents of the Company or any applicable written agreement between you and the Company, (y) rights under ERISA or (z) rights
which, as a matter of law, cannot be waived. The Separation Agreement must be in substantially the form reasonably prescribed by the Company, and must be executed and must become enforceable and irrevocable on or before the 52nd day following your
last day of employment with the Company. If you fail to execute without revocation the Separation Agreement on or before the 52nd day following your last day of employment with the Company, you shall be entitled to the Accrued Obligations only and
no other severance payments or benefits. The continued salary provided under Section 6(b)(ii) below shall be paid in accordance with the Company’s normal payroll practices and shall commence on the next payroll date falling after the date
the Separation Agreement becomes enforceable and irrevocable. If, however, the 52-day period in which the Separation Agreement must become enforceable and irrevocable begins in one taxable year and ends in the
following year, the Company shall commence payment of the continued salary in the second year on the first payroll date falling on the later of: (A) January 1; and (B) the date on which the Separation Agreement becomes enforceable and
irrevocable. The first payroll shall include, however, all amounts that would otherwise have been paid to you between the date your employment is terminated and your receipt of the first installment. 

b. Severance. If you are subject to an Involuntary Termination, then, subject to Section 6(a): 

i. The Company shall pay you the Accrued Obligations earned through your last day of employment on or before the time required by law but in no
event more than fifteen (15) days after your last day of employment with the Company, except to the extent such payment would accelerate compensation in a manner inconsistent with compliance with Section 409A of the Internal Revenue Code
of 1986, as amended (the “Code”); 
 ii. If the Involuntary Termination occurs prior to a Change in Control or more than
twelve (12) months following a Change in Control, the Company will pay you as severance pay an aggregate amount equivalent to twelve (12) months of your then current annualized Base Salary plus a
pro-rated amount of the Target Bonus for the year in which the Involuntary Termination occurs, less all applicable taxes and withholdings, which severance pay will be paid ratably over a period of twelve (12)

  
 3 

 
months. If the Involuntary Termination occurs upon, or within twelve (12) months following, a Change in Control (a “Change in Control Involuntary Termination”), then, in
lieu of the foregoing, the Company will pay you as severance pay an aggregate amount equivalent to eighteen (18) months of your then current annualized Base Salary plus a pro-rated amount of the Target
Bonus f or the year in which the Change in Control Involuntary Termination occurs, less all applicable taxes and withholdings, which severance pay will be paid ratably over a period of eighteen (18) months; 

iii. Should you be eligible for and timely elect to continue receiving group health insurance coverage under the law known as COBRA, the
Company shall pay on your behalf the portion of the monthly premiums for such coverage that it pays for active and similarly situated employees receiving the same type of coverage, for a period ending upon the earlier of (x) the twelve
(12)-month anniversary of your termination date (or the eighteen (18)-month anniversary in the case of a Change in Control Involuntary Termination), and (y) the date on which you become eligible to receive group health insurance coverage
through another employer (as applicable, the “COBRA Contribution Period”); provided, however, that such Company-paid premiums may be recorded as additional income pursuant to Section 6041 of the Code and not entitled to any tax
qualified treatment to the extent necessary to comply with or avoid the discriminatory treatment prohibited by the Patient Protection and Affordable Care Act of 2010 and the Health Care and Education Reconciliation Act of 2010 or Section 105(h)
of the Code. The balance of such premiums during the COBRA Contribution Period, and all premium costs thereafter, shall be paid by you on a monthly basis during the elected period of health insurance coverage under COBRA for as long as, and to the
extent that, you remain eligible for and elect to remain enrolled in COBRA continuation coverage. You agree that, should you become eligible to receive group health insurance coverage through another employer prior to the twelve (12)-month
anniversary of your termination date (or the eighteen (18)-month anniversary in the case of a Change in Control Involuntary Termination), you shall immediately notify the Company in writing of the date of eligibility for such coverage and the
Company’s obligation under this paragraph shall terminate as of such date of eligibility. 
 iv. If the Involuntary Termination
constitutes a Change in Control Involuntary Termination, then one hundred percent (100%) of the unvested portion of the Option Grants and each Additional Grant then subject to vesting will fully vest as of the date of such Change in Control
Involuntary Termination. If the Involuntary Termination does not constitute a Change in Control Involuntary Termination, then the unvested portion of the Option Grants and each Additional Grant then subject to vesting that would have otherwise
vested on or prior to the first anniversary of such Involuntary Termination if you had remained employed with the Company through such date will fully vest as of the date of such Involuntary Termination. In the event of any acceleration under this
Section 6(b)(iv), no shares may be transferred and no stock option exercised (in each case with respect to the unvested portion) until the Separation Agreement has become enforceable and irrevocable and if the Separation Agreement does not
become enforceable and irrevocable in accordance with this offer letter, the portions of the Option Grants and Additional Grants that have vested as a result of this Section 6(b)(iv) shall be cancelled effective as of the date of the
Involuntary Termination. The payments and benefits described in Section 6(b)(ii)-(iv) above shall hereinafter be referred to as the “Severance.” If you are terminated for any reason other than as result of an Involuntary
Termination, you shall be entitled to receive the Accrued Obligations only. 
 7. Representation Regarding Continuing Obligations. Your employment is
contingent upon your signing and adhering to an Invention and Non-Disclosure Agreement (the “Restrictive Covenant Agreement”), a copy of which is provided with this letter. You hereby
represent to the Company that you are not a party to any agreement of any type which may impact or limit your ability to become employed by or perform your job at the Company or which is in any way inconsistent with the terms of this offer letter or
the Restrictive Covenant Agreement. You represent that you will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any current or previous employer or any other party.
Further, you hereby represent that (i) your employment with the 

  
 4 

 
Company and this offer letter does not and will not violate or conflict with any obligations you may have to or any agreements you may have with any former employer and (ii) you have
provided the Company with all written agreements that describe any continuing post-employment obligations to any former employer. 
 8. Proof of Legal
Right to Work. You agree to provide to the Company, within three (3) days of the Start Date, documentation proving your eligibility to work in the United States, as required by the Immigration Reform and Control Act of 1986. You may need a
work visa in order to be eligible to work in the United States. If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company. 

9. Tax Matters. 
 a. All forms of
compensation referred to in this offer letter are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation
policies in a manner that minimizes your tax liabilities and that you are solely responsible for individual tax liabilities arising from your compensation. 

b. For purposes of Section 409A of the Code, each salary continuation payment under Section 6(b)(ii) is hereby designated as a
separate payment. If the Company determines that you are a “specified employee” under Section 409A(a)(2)(B)(i) of the Code at the time of your Separation, then (i) the salary continuation payments under
Section 6(b)(ii), to the extent that they are subject to Section 409A of the Code, will commence on the first business day following (A) expiration of the six-month period measured from your
Separation, or (B) the date of your death, and (ii) the installments that otherwise would have been paid prior to such date will be paid in a lump sum when the salary continuation payments commence. Any salary continuation payments that
are not subject to Section 409A of the Internal Revenue Code, including, without limitation, payments that are exempt from Section 409A of the Internal Revenue Code as a result of the separation pay plan exemption under Section 1.409A-1(b)(9) of the Internal Revenue Code (or any successor thereto), will continue to be paid as otherwise provided in this offer letter. 

c. All in-kind benefits provided and expenses eligible for reimbursement hereunder shall be provided
by the Company or incurred by you during your employment with the Company. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the
taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the
in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to
liquidation or exchange for another benefit. 
 10. Interpretation, Amendment and Enforcement. This offer letter and the Grant Documents along with
the Restrictive Covenant Agreement constitute the complete agreement between you and the Company, contain all the terms of your employment, and supersede any prior agreements, representations or understandings (whether written, oral or implied)
between you and the Company relating to the terms of your employment. The terms of this offer letter and the resolution of any disputes as to the meaning, effect, performance or validity of this offer letter or arising out of, related to, or in any
way connected with, this offer letter, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by Massachusetts law, excluding laws relating to conflicts or choice of
law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute. 

  
 5 

 11. Other Terms. This letter shall not be construed as an agreement, either express or implied, to
employ you for any stated term, and shall in no way alter the Company’s policy of employment at-will as defined by applicable law, which means that you have the right to terminate your employment
relationship with the Company at any time f or any reason and the Company has the right to terminate its employment relationship with you at any time f or any reason, with or without cause or notice. Similarly, nothing in this letter shall be
construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company other than as provided in this letter. 

12. Definitions. The following terms have the meaning set forth below wherever they are used in this letter agreement: 

a. “Accrued Obligations” means: (i) any earned but unpaid Base Salary as of the date your employment is terminated,
(ii) any accrued, but unused vacation time as of your termination date, (iii) any vested benefits you may have under any employee benefit plan of the Company as of your termination date, (iv) any unpaid expense reimbursements accrued
prior to the date your employment is terminated, and (iv) any bonus for a fiscal year preceding the year in which your employment is terminated that was earned and Board- approved but is unpaid as of the date your employment is terminated. 

b. “Cause” means (i) your material breach of the Restrictive Covenant Agreement, (ii) your conviction of, or your
plea of “guilty” or “no contest” to, a felony under the laws of the United States or any State, (iii) your gross negligence or willful misconduct in the performance of your duties, (iv) your material continuing failure
to perform assigned duties after receiving written notification of the material failure from the Company or (v) your failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or
employees, if the Company has requested your cooperation; provided, however, that “Cause” shall not be deemed to have occurred pursuant to subsection (iii), (iv), or (v) hereof unless you have first received written notice from
the Board specifying in reasonable detail the particulars of such grounds and that the Company intends to terminate your employment hereunder for such grounds and you have failed to cure such grounds within a period of thirty (30) days from the
date of such notice. 
 c. “Change in Control” means the occurrence of any one or more of the following events, in each
case only to the extent that such event also constitutes a “change in ownership” of the Company or a “change in the ownership of a substantial part of the Company’s assets” for the purposes of Section 409A of the Code:
(i) the consummation of a merger or consolidation of the Company with any other entity, other than a merger or consolidation in which voting securities of the Company outstanding immediately prior thereto continue to represent more than fifty
percent (50%) percent of the total voting power of: (A) the surviving or resulting corporation; or (B) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or
consolidation, the parent corporation of such surviving or resulting corporation immediately after such merger or consolidation; (ii) the acquisition of all of the Company’s outstanding capital stock by a single person or entity or a group
acting in concert to effect such acquisition; or (iii) the sale, transfer or exclusive license of all or substantially all of the assets of the Company. 

d. “Expenses” means any damages, losses, judgments, liabilities, fines, penalties, excise taxes, settlements, costs,
attorneys’ fees, accountants’ fees, and disbursements and costs of attorneys and accountants. 
 e. “Involuntary
Termination” means either: (i) your Termination Without Cause or (ii) your Resignation for Good Reason. 

  
 6 

 f. “Resignation for Good Reason” means a Separation as a result of your
resignation after one of the following conditions has come into existence without your consent: 
 i. A reduction in your Base Salary
(unless such reduction is part of a broad-based salary reduction applicable to the Company’s senior management) or Target Bonus percentage; 

ii. A material diminution of your authority, duties or responsibilities; 

iii. Forced permanent relocation of your primary working location with the Company by more than 35 miles from your current working location;

 iv. Your removal as Chief Executive Officer of the Company (or if following a Change in Control, you are not appointed as, or are
removed as, Chief Executive Officer of the combined company resulting from, or if applicable, the ultimate parent entity of the acquiring party in, such Change in Control); or 

v. The Company’s failure to have any successor assume the obligations under this letter agreement. 

Notwithstanding the foregoing, a Resignation for Good Reason will not be deemed to have occurred unless (i) you give the Company written
notice of the condition within ninety (90) days after the condition comes into existence, (ii) the Company fails to remedy the condition within thirty (30) days after receiving your written notice (the “Cure Period”)
and (iii) you resign within thirty (30) days after the expiration of the Cure Period. 
 g. “Separation” means a
“separation from service,” as defined in the regulations under Section 409A of the Code. 
 h. “Termination Without
Cause” means a Separation as a result of a termination of your employment by the Company without Cause, provided you are willing and able to continue performing services within the meaning of Treasury Regulation 1.409A-1(n)(1). 

  
 7 

 We are excited about the prospect of having you join the Company. If this letter correctly
sets forth the terms under which you will be employed by the Company, please sign this letter in the space provided below and return it to me, along with a signed copy of the Restrictive Covenant Agreement by July 5, 2021. If you do not accept
this of fer by July 5, 2021, then this offer will be deemed revoked. 
  

	
	Very truly yours,
	
	Third Harmonic Bio, Inc.
	
	/s/ Mark Iwicki
	Mark Iwicki
	Chairman of the Board

 The foregoing correctly sets forth the terms of my at-will employment with Third
Harmonic Bio, Inc. I am not relying on any representations other than those set forth above. 
  

					
	/s/ Natalie Holles	 		 	7/2/2021
	By: Natalie Holles	 		 	Date

  
 1 

 Exhibit A 

Permitted Activities 
 Membership on the board of
directors of Rubius Therapeutics, Inc. and Day One Biopharmaceuticals, Inc. 

 Exhibit B 

Form of Secured Partial Recourse Promissory NoteEX-10.9

 Exhibit 10.9 

PROJECT IGE, INC. 

CONSULTING AGREEMENT 

This Consulting Agreement (the “Agreement”) made this 14th day of June, 2019 (the “Effective Date”) is
entered into by Project IGE, Inc., a Delaware corporation (the “Company”), and Mark Iwicki, an individual residing at [                ] (the
“Consultant”). 
 WHEREAS, the Company and the Consultant desire to establish the terms and conditions under which the
Consultant will provide services to the Company. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained
herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, the parties agree as follows: 

1. Services. The Consultant agrees to perform such consulting, advisory and related services to and for the Company as may be reasonably
requested from time to time by the Company, including, but not limited to, the services specified on Schedule A to this Agreement. The Consultant also agrees to provide the Company with related services that may be requested from time to time
by the Company. 
 2. Term. This Agreement shall commence on the date hereof and shall continue until June 14, 2023 (such period,
as it may be extended or sooner terminated in accordance with the provisions of Section 4, being referred to as the “Consultation Period”). 

3. Compensation. 
 3.1
Consulting Fees. In consideration for the Consultant’s services, the Company shall grant to the Consultant, subject to the approval of the Company’s Board of Directors and the execution of a restricted stock agreement, a restricted
stock award for 106,400 shares of the Company’s common stock (the “Shares”), which shall vest in equal monthly installments of 1/48th of the Shares following the Effective
Date until the fourth anniversary of the Effective Date. The Shares shall otherwise be subject to the terms and conditions of the restricted stock agreement, which shall be in a form approved by the Company’s Board of Directors. 

3.2 Expenses. The Company shall reimburse the Consultant for all reasonable and necessary documented out of pocket expenses incurred or
paid by the Consultant in connection with, or related to, the performance of Consultant’s services under this Agreement. The Consultant shall submit to the Company itemized monthly statements, in a form satisfactory to the Company, of such
expenses incurred in the previous month. The Company shall pay to the Consultant amounts shown on each such statement within thirty (30) days after receipt thereof. Notwithstanding the foregoing, the Consultant shall not incur total expenses in
excess of $500.00 per month without the prior written approval of the Company. 

 3.3 Benefits. The Consultant shall not be entitled to any benefits, coverages or
privileges, including, without limitation, health insurance, social security, unemployment, medical or pension payments, made available to employees of the Company. 

4. Termination. This Agreement may be terminated in the following manner: (a) by either the Company or the Consultant upon not less
than thirty (30) days prior written notice to the other party; (b) by the non-breaching party, upon twenty-four (24) hours prior written notice to the breaching party if one party has materially
breached this Agreement; or (c) at any time upon the mutual written consent of the parties hereto. In the event of termination, the Consultant shall be entitled to payment for services performed and (subject to the limitation in
Section 3.2) for expenses paid or incurred prior to the effective date of termination that have not been previously paid. Such payment shall constitute full settlement of any and all claims of the Consultant of every description against the
Company. Notwithstanding the foregoing, the Company may terminate this Agreement effective immediately by giving written notice to the Consultant if the Consultant breaches or threatens to breach any provision of Sections 6, 7 or 10. 

5. Cooperation. The Consultant shall use Consultant’s best efforts in the performance of Consultant’s obligations under this
Agreement. The Company shall provide such access to its information and property as may be reasonably required in order to permit the Consultant to perform Consultant’s obligations hereunder. The Consultant shall cooperate with the
Company’s personnel, shall not interfere with the conduct of the Company’s business and shall observe all rules, regulations and security requirements of the Company concerning the safety of persons and property. 

6. Proprietary Information and Inventions. 

6.1 Proprietary Information. 

(a) The Consultant acknowledges that Consultant’s relationship with the Company is one of high trust and confidence and that in the
course of Consultant’s service to the Company, Consultant will have access to and contact with Proprietary Information. The Consultant will not disclose any Proprietary Information to any person or entity other than employees of the Company or
use the same for any purposes (other than in the performance of the services) without written approval by an officer of the Company, either during or after the Consultation Period, unless and until such Proprietary Information has become public
knowledge without fault by the Consultant. 
 (b) For purposes of this Agreement, Proprietary Information shall mean, by way of illustration
and not limitation, all information, whether or not in writing, whether or not patentable and whether or not copyrightable, of a private, secret or confidential nature, owned, possessed or used by the Company, concerning the Company’s business,
business relationships or financial affairs, including, without limitation, any Invention, formula, vendor information, customer information, apparatus, equipment, trade secret, process, research, report, technical or research data, clinical data, know-how, computer program, software, software documentation, hardware design, technology, product, processes, methods, techniques, formulas, compounds, projects, developments, marketing or business plan, forecast,
unpublished financial statement, budget, license, price, cost, customer, supplier or personnel information or employee list that is communicated to, learned of, developed or otherwise acquired by the Consultant in the course of Consultant’s
service as a consultant to the Company. 

  
 - 2 - 

 (c) The Consultant’s obligations under this Section 6.1 shall not apply to any
information that (i) is or becomes known to the general public under circumstances involving no breach by the Consultant or others of the terms of this Section 6.1, (ii) is generally disclosed to third parties by the Company without
restriction on such third parties, or (iii) is approved for release by written authorization of an officer of the Company. 
 (d) The
Consultant agrees that all files, documents, letters, memoranda, reports, records, data, sketches, drawings, models, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other
tangible material containing Proprietary Information, whether created by the Consultant or others, which shall come into Consultant’s custody or possession, shall be and are the exclusive property of the Company to be used by the Consultant
only in the performance of Consultant’s duties for the Company and shall not be copied or removed from the Company premises except in the pursuit of the business of the Company. All such materials or copies thereof and all tangible property of
the Company in the custody or possession of the Consultant shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) the termination of this Agreement. After such delivery, the Consultant shall not retain
any such materials or copies thereof or any such tangible property. 
 (e) The Consultant agrees that Consultant’s obligation not to
disclose or to use information and materials of the types set forth in paragraphs (b) and (d) above, and Consultant’s obligation to return materials and tangible property set forth in paragraph (d) above extends to such types of
information, materials and tangible property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Consultant. 

(f) The Consultant acknowledges that the Company from time to time may have agreements with other persons or with the United States
Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. The Consultant agrees to be bound by
all such obligations and restrictions that are known to Consultant and to take all action necessary to discharge the obligations of the Company under such agreements. 

6.2 Inventions. 
 (a) All
inventions, ideas, creations, discoveries, computer programs, works of authorship, data, developments, technology, designs, innovations and improvements (whether or not patentable and whether or not copyrightable) which are made, conceived, reduced
to practice, created, written, designed or developed by the Consultant, solely or jointly with others or under Consultant’s direction and whether during normal business hours or otherwise, (i) during the Consultation Period if related to
the business of the Company or (ii) after the Consultation Period if resulting or directly derived from Proprietary Information (as defined above) (collectively under clauses (i) and (ii), “Inventions”), shall be the sole
property 

  
 - 3 - 

 
of the Company. The Consultant hereby assigns to the Company all Inventions and any and all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property
rights and applications therefor, in the United States and elsewhere and appoints any officer of the Company as Consultant’s duly authorized attorney to execute, file, prosecute and protect the same before any government agency, court or
authority. However, this paragraph shall not apply to Inventions which do not relate to the business or research and development conducted or planned to be conducted by the Company at the time such Invention is created, made, conceived or reduced to
practice and which are made and conceived by the Consultant not during normal working hours, not on the Company’s premises and not using the Company’s tools, devices, equipment or Proprietary Information. The Consultant further
acknowledges that each original work of authorship which is made by the Consultant (solely or jointly with others) within the scope of this Agreement and which is protectable by copyright is a “work made for hire,” as that term is defined
in the United States Copyright Act. 
 (b) The Consultant agrees that if, in the course of performing the Services, the Consultant
incorporates into any Invention developed under this Agreement any preexisting invention, improvement, development, concept, discovery or other proprietary information owned by the Consultant or in which the Consultant has an interest
(“Prior Inventions”), (i) the Consultant will inform the Company, in writing before incorporating such Prior Inventions into any Invention, and (ii) the Company is hereby granted a nonexclusive, royalty-free, perpetual,
irrevocable, transferable worldwide license with the right to grant and authorize sublicenses, to make, have made, modify, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform, and
otherwise exploit such Prior Inventions, without restriction, including, without limitation, as part of or in connection with such Invention, and to practice any method related thereto. The Consultant will not incorporate any invention, improvement,
development, concept, discovery or other proprietary information owned by any third party into any Invention without the Company’s prior written permission. 

(c) Upon the request of the Company and at the Company’s expense, the Consultant shall execute such further assignments, documents and
other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in the United States and in any
foreign country with respect to any Invention. The Consultant also hereby waives all claims to moral rights in any Inventions. 
 (d) The
Consultant shall promptly disclose to the Company all Inventions and will maintain adequate and current written records (in the form of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual
reduction to practice of any Invention. Such written records shall be available to and remain the sole property of the Company at all times. 

7. Non-Solicitation. During the Consultation Period and for a period of six (6) months
thereafter, the Consultant shall not, either alone or in association with others, (i) solicit, or permit any organization directly or indirectly controlled by the Consultant to solicit, any employee of the Company to leave the employ of the
Company; (ii) solicit for employment, hire or engage as an independent contractor, or permit any organization directly or indirectly 

  
 - 4 - 

 
controlled by the Consultant to solicit for employment, hire or engage as an independent contractor, any person who is employed or engaged by the Company; and/or (iii) solicit, divert or
take away, the business or patronage of any of the clients, customers or accounts or prospective clients, customers or accounts, of the Company that were contacted, solicited or served by the Consultant on behalf of the Company during the term of
the Consultant’s engagement with the Company. 
 8. Other Agreements: Warranty. 

8.1 The Consultant hereby represents that, except as the Consultant has disclosed in writing to the Company, the Consultant is not bound by the
terms of any agreement with any third party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of Consultant’s consultancy with the Company, to refrain from competing, directly or
indirectly, with the business of such third party or to refrain from soliciting employees, customers or suppliers of such third party. The Consultant further represents that Consultant’s performance of all the terms of this Agreement and the
performance of the services as a consultant of the Company do not and will not breach any agreement with any third party to which the Consultant is a party (including, without limitation, any nondisclosure or
non-competition agreement), and that the Consultant will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any current or previous
employer or others. 
 8.2 Consultant hereby represents, warrants and covenants that Consultant (a) will perform such services in a
professional, competent and timely manner, (b) will render such services in compliance with all applicable laws, rules and regulations, including but not limited to the U.S. Food, Drug and Cosmetic Act, as amended from time to time and
(c) has not been debarred and is not under consideration to be debarred by the U.S. Food and Drug Administration from working in or providing consulting services to any pharmaceutical or biotechnology company under the Generic Drug Enforcement
Act of 1992. Further, Consultant hereby represents, warrants and covenants that Consultant has the power to enter into this Agreement and that Consultant’s performance hereunder will not infringe upon or violate the rights of any third party or
violate any federal, state or municipal laws. If Consultant is a faculty member at or employee of a university or hospital or of another company (“Institution”), Consultant represents, warrants and covenants that, pursuant to such
Institution’s policies concerning professional consulting and additional workload, Consultant is permitted to enter into this Agreement. 

8.3 Consultant consents to the use by the Company of his name, biographical information and likeness on its website, in its written materials,
and in its oral presentations, provided that such website, materials or presentations accurately describe the Consultant and the nature of Consultant’s relationship with or contribution to the Company. 

9. Independent Contractor Status. 

9.1 The Consultant shall perform all services under this Agreement as an “independent contractor” and not as an employee or agent of
the Company. The Consultant is not authorized to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, the Company or to bind the Company in any manner. 

  
 - 5 - 

 9.2 The Consultant shall have the right to control and determine the time, place, methods,
manner and means of performing the services. In performing the services, the amount of time devoted by the Consultant on any given day will be entirely within the Consultant’s control, and the Company will rely on the Consultant to put in the
amount of time necessary to fulfill the requirements of this Agreement. The Consultant will provide all equipment and supplies required to perform the services. The Consultant is not required to attend regular meetings at the Company. However, upon
reasonable notice, the Consultant shall meet with representatives of the Company at a location to be designated by the parties to this Agreement. 

9.3 In the performance of the services, the Consultant has the authority to control and direct the performance of the details of the services,
the Company being interested only in the results obtained. However, the services contemplated by the Agreement must meet the Company’s standards and approval and shall be subject to the Company’s general right of inspection and supervision
to secure their satisfactory completion. 
 9.4 The Consultant shall not use the Company’s trade names, trademarks, service names or
service marks without the prior approval of the Company. 
 9.5 The Consultant shall be solely responsible for all state and federal income
taxes, unemployment insurance and social security taxes in connection with this Agreement and for maintaining adequate workers’ compensation insurance coverage and shall indemnify, defend and hold harmless the Company and its successors and
assigns from and against any claim, demand, liability, damage, cost or expense (including without limitation attorneys’ fees, back wages, liquidated damages, penalties or interest) resulting from Consultant’s failure to pay such taxes and
associated penalties and payments and to maintain such coverage. 
 10. Non-Exclusivity and Non-Competition. The Consultant retains the right to contract with other companies or entities for Consultant’s consulting services without restriction; provided, that during the Consultation Period,
the Consultant may not contract with any business or enterprise that is competitive with the Company’s business. For the avoidance of doubt, the Company acknowledges and agrees that Consultant’s role as a director of Aimmune Therapeutics,
Inc. does not and will not violate or conflict with the Consultant’s obligations under this Section 10. The Company retains a right to contract with other companies and/or individuals for consulting services without restriction. 

11. Remedies. The Consultant acknowledges that any breach of the provisions of Sections 6, 7 or 10 of this Agreement shall result in
serious and irreparable injury to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Consultant agrees, therefore, that, in addition to any other remedy the Company may have, the Company shall be
entitled to enforce the specific performance of this Agreement by the Consultant and to seek both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving actual damages or posting a bond. 

  
 - 6 - 

 12. Notices. All notices required or permitted under this Agreement shall be in
writing and shall be deemed effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or
addresses as either party shall designate to the other in accordance with this Section 12. 
 13. Pronouns. Whenever the context
may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 

14. Entire Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and
understandings, whether written or oral, relating to the subject matter of this Agreement. 
 15. Amendment. This Agreement may be
amended or modified only by a written instrument executed by both the Company and the Consultant. 
 16.
Non-Assignability of Contract. This Agreement is personal to the Consultant and the Consultant shall not have the right to assign any of Consultant’s rights or delegate any of Consultant’s
duties without the express written consent of the Company. Any non-consented-to assignment or delegation, whether express or implied or by operation of law, shall be
void and shall constitute a breach and a default by the Consultant. 
 17. Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the Commonwealth of Massachusetts without giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction. 

18. Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective
successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the Consultant are personal and shall not be assigned
by Consultant. 
 19. Interpretation. If any restriction set forth in Section 6 or Section 7 or Section 10 is found by
any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of
time, range of activities or geographic area as to which it may be enforceable. 
 20. Survival. Sections 4 through 21 shall survive
the expiration or termination of this Agreement. 
 21. Miscellaneous. 

21.1 No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A
waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. 

  
 - 7 - 

 21.2 The captions of the sections of this Agreement are for convenience of reference only
and in no way define, limit or affect the scope or substance of any section of this Agreement. 
 21.3 In the event that any provision of
this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

[Remainder of Page Intentionally Left Blank] 

  
 - 8 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Consulting
Agreement as of the date and year first above written. 
  

			
	 COMPANY:
  

PROJECT IGE, INC.

		
	By:	 	 /s/ Michael Gladstone

	Name: Michael Gladstone
	Title:   President and CEO
	
	CONSULTANT:
		
	By:	 	 /s/ Mark Iwicki

	Name: Mark Iwicki

  

  
 SIGNATURE PAGE TO
CONSULTING AGREEMENT 

 SCHEDULE A 

DESCRIPTION OF SERVICES 
  

	 	•	 	 Advise on corporate and research and development strategies of the Company

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]